Avantor (AVTR): Early Signs of Turnaround Under New Leadership

Avantor (AVTR) has taken its first steps toward stabilization under new CEO Emmanuel Ligner. The company reported $1.58 billion in revenue in Q2 2026, down 4% organically, but with a book-to-bill ratio above 1 and operational improvements like VWR's new website, signaling a promising second half. Longleaf Partners found Avantor attractive based on P/FCF metrics, though it noted higher risk compared to AI alternatives. With 47 hedge funds now holding AVTR, the stock remains under scrutiny. Market watchers are monitoring Avantor's improved order-to-ship patterns in bioprocessing and the impact of Merck's Bio-Techne acquisition, which highlights the sector's ongoing appeal. The stock's 42.96% 52-week decline and 10.35% monthly gain reflect investor sentiment. These developments suggest the new leadership is focused on long-term strategic goals. Merck's EBITDA multiple on Bio-Techne underscores the biotech sector's continued attractiveness.

Avantor's new management is aggressively improving operational efficiency, which should boost FCF generation and strengthen the company's EBITDA multiple in the long run. Markets will closely follow this transformation process.